- Home
- VET vs ADPT Comparison
VET vs ADPT Comparison
Compare VET & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VET
- ADPT
- Stock Information
- Founded
- VET 1994
- ADPT 2009
- Country
- VET Canada
- ADPT United States
- Employees
- VET N/A
- ADPT N/A
- Industry
- VET Oil & Gas Production
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VET Energy
- ADPT Health Care
- Exchange
- VET Nasdaq
- ADPT Nasdaq
- Market Cap
- VET 994.1M
- ADPT 1.1B
- IPO Year
- VET N/A
- ADPT 2019
- Fundamental
- Price
- VET $6.41
- ADPT $9.03
- Analyst Decision
- VET
- ADPT Buy
- Analyst Count
- VET 0
- ADPT 6
- Target Price
- VET N/A
- ADPT $9.83
- AVG Volume (30 Days)
- VET 1.3M
- ADPT 3.0M
- Earning Date
- VET 05-07-2025
- ADPT 05-01-2025
- Dividend Yield
- VET 5.47%
- ADPT N/A
- EPS Growth
- VET N/A
- ADPT N/A
- EPS
- VET N/A
- ADPT N/A
- Revenue
- VET $1,281,132,639.00
- ADPT $189,527,000.00
- Revenue This Year
- VET $37.29
- ADPT $21.20
- Revenue Next Year
- VET N/A
- ADPT $21.99
- P/E Ratio
- VET N/A
- ADPT N/A
- Revenue Growth
- VET N/A
- ADPT 8.61
- 52 Week Low
- VET $5.14
- ADPT $2.99
- 52 Week High
- VET $12.68
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- VET 47.39
- ADPT 57.82
- Support Level
- VET $5.90
- ADPT $8.38
- Resistance Level
- VET $6.33
- ADPT $9.51
- Average True Range (ATR)
- VET 0.26
- ADPT 0.66
- MACD
- VET 0.07
- ADPT 0.16
- Stochastic Oscillator
- VET 60.00
- ADPT 63.02
About VET Vermilion Energy Inc. Common (Canada)
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).